AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $263.41
- 52-wk high
- $282.15
- High
- $272.47
- 52-wk low
- $186.05
- Low
- $262.32
- Prev close
- $270.56
- Mkt cap
- $17.72B
- P/E
- 20.8x
- Volume
- 653.4K
- Fwd P/E
- 24.0x
- Beta
- 0.48
- P/S
- 16.9x
- P/B
- 10.7x
- Profit margin
- +70.9%
- Op margin
- +65.0%
- ROE
- +118.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Earnings
Earnings came in $2.51 a share above what analysts expected.
Earnings per share
$0.78 expected
What the street expects next
EPS expected
$0.68 to $1.09
Revenue expected
15 analysts
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Jun 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|
| What came in | |||
| Revenue | $36.0M | $57.8M | $101.0M |
| Cost of what it sold | $11.5M | $11.2M | $17.5M |
| Gross profit | $24.5M | $46.6M | $83.4M |
| What it spent | |||
| Research and development | $83.5M | $73.5M | $86.6M |
| Sales and admin | $72.3M | $68.1M | $95.6M |
| Other operating costs | $2.0M | $1.7M | $5.4M |
| Total operating expenses | $157.8M | $143.4M | $187.6M |
| What was left | |||
| Operating profit | -$133.3M | -$96.7M | -$104.2M |
| Interest on debt | $19.6M | $25.3M | $44.8M |
| Profit before tax | -$109.2M | -$98.2M | -$93.6M |
| Tax | $229.0K | $1.0M | $1.1M |
| Net profit | -$109.4M | -$99.2M | -$94.6M |
| EBITDA | -$87.5M | -$71.1M | -$44.2M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
BullishAug 31Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
BullishAug 31If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today
BullishAug 27Ascendis to present 2-year achondroplasia trial data at ISDS
BullishAug 26Ascendis Announces Oral Presentation of Week 104 Data from
BullishAug 26Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
BullishAug 25
Macro
30 macro signals shaping ASND right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results